MARKET

KDNY

KDNY

Chinook Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.31
+0.31
+1.82%
After Hours: 17.31 0 0.00% 16:01 03/05 EST
OPEN
16.79
PREV CLOSE
17.00
HIGH
17.36
LOW
16.54
VOLUME
227.37K
TURNOVER
--
52 WEEK HIGH
21.68
52 WEEK LOW
9.35
MARKET CAP
729.76M
P/E (TTM)
-4.8135
1D
5D
1M
3M
1Y
5Y
Chinook Therapeutics to Present at Upcoming Investor Conferences
VANCOUVER, British Columbia and SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today...
GlobeNewswire · 5d ago
Will Chinook Therapeutics (KDNY) Report Negative Q4 Earnings? What You Should Know
Zacks.com · 6d ago
Analysts Offer Insights on Healthcare Companies: Chinook Therapeutics (KDNY) and Krystal Biotech (KRYS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chinook Therapeutics (KDNY) and Krystal Biotech (KRYS) with
SmarterAnalyst · 6d ago
Chinook Therapeutics Collaborates With Evotec to Develop Medicines for Chronic Kidney Diseases
MT Newswires · 6d ago
Chinook Therapeutics, Evotec Announce Strategic Collaboration To 'Discover And Develop Novel Precision Medicines For Chronic Kidney Diseases'
Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases Collaboration will Leverage Access to the NURTuRE Patient Biobank and
Benzinga · 6d ago
Evotec, Chinook Therapeutics Ink Development Pact For Chronic Kidney Diseases Therapies
Chinook Therapeutics Inc (NASDAQ: KDNY) and Evotec SE (OTCMKTS: EVTCY) have 
Benzinga · 6d ago
BRIEF-Evotec Enters Strategic Partnership WIth Chinook For Chronic Kidney Disease
reuters.com · 6d ago
Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit
Head of Renal Discovery and Translational Medicine, Andrew King, D.V.M., Ph.D., to Present on Atrasentan and Participate in Expert Panel Discussion on Executing Precision Medicine in Clinical Trials VANCOUVER, British Columbia and SEATTLE, Feb. 23, 2021 (G...
GlobeNewswire · 02/23 13:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KDNY. Analyze the recent business situations of Chinook Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KDNY stock price target is 30.33 with a high estimate of 38.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 162
Institutional Holdings: 25.22M
% Owned: 59.81%
Shares Outstanding: 42.16M
TypeInstitutionsShares
Increased
27
3.94M
New
41
12.39M
Decreased
17
4.25M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
President/Chief Executive Officer/Director
Eric Dobmeier
Chief Financial Officer
Eric Bjerkholt
Other
Tom Frohlich
Other
Alan Glicklich
Director
Srinivas Akkaraju
Director
Jerel Davis
Director
Michelle Griffin
Director
Dolca Thomas
Independent Director
William Greenman
Independent Director
Ross Haghighat
No Data
  • All
  • Financials
  • Insiders
More
About KDNY
Chinook Therapeutics, Inc., formerly Aduro Biotech, Inc., is a clinical-stage biotechnology company. The Company develops precision medicines for kidney diseases. The Company’s products focus on severe chronic kidney disorders. The Company assembled a portfolio of precision medicines product candidates designed to address severe chronic kidney diseases. Its development programs consist of atrasentan, BION-1301 and CHK-336. Atrasentan, a potent and selective endothelin receptor antagonist that the Company is developing for treatment of primary glomerular diseases, including IgAN. IgAN is a serious progressive autoimmune disease of the kidney. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase 1b trial for IgA nephropathy. CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other chronic kidney diseases, including polycystic kidney disease.

Webull offers kinds of Chinook Therapeutics Inc stock information, including NASDAQ:KDNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KDNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KDNY stock methods without spending real money on the virtual paper trading platform.